**Name of Journal:** *World Journal of Experimental Medicine*

**Manuscript NO:** 72831

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Comparison between SARS-CoV-2 positive and negative pneumonia in children: A retrospective analysis at the beginning of the pandemic**

Zhamankulov A *et al*. Pediatric SARS-CoV-2 positive and negative pneumonia

Adil Zhamankulov, Rafail Rozenson, Marina Morenko, Ulzhan Akhmetova, Alina Tyo, Dimitri Poddighe

**Adil Zhamankulov, Rafail Rozenson, Marina Morenko, Ulzhan Akhmetova, Alina Tyo,** Department of Children's diseases, Astana Medical University, First Children's Municipal Hospital, Nur-Sultan 010000, Kazakhstan

**Dimitri Poddighe,** Clinical Academic Department of Pediatrics, National Research Center for Maternal and Child Health, University Medical Center, Nur-Sultan 010000, Kazakhstan

**Author contributions:** Zhamankulov A and Rozenson R conceived the study; Zhamankulov A, Morenko M, Akhmetova U, Tyo A collected and provided the data; Zhamankulov A and Poddighe D organized and analyzed the data; Rozenson R, Morenko M, Poddighe D provided intellectual contribution; Zhamankulov A and Poddighe D wrote the manuscript; all authors have read and agreed to the published version of the manuscript.

**Corresponding author: Dimitri Poddighe, MD, MSc, PhD, Associate Professor, Director, Doctor,** Pediatrics, National Research Center for Maternal and Child Health, No. 32 Turan Avenue, Nur-Sultan 010000, Kazakhstan. dimitri.poddighe@nu.edu.kz

**Received:** October 30, 2021

**Revised:** December 29, 2021

**Accepted:** February 27, 2022

**Published online:** March 20, 2022

**Abstract**

BACKGROUND

Even though coronavirus 2019 disease (COVID-19) clinical course in children is much milder than in adults, pneumonia can occur in the pediatric population as well. Here, we reported a single-center pediatric case series of COVID-19 from Kazakhstan during the first wave of pandemic.

AIM

To analyze the main clinical and laboratory aspects in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) positive and negative children diagnosed with pneumonia.

METHODS

This is a retrospective analysis of 54 children, who were medically assessed as close contacts of COVID-19 adults in their family setting, between June and September 2020. These children were all hospitalized: We compared the clinical and laboratory characteristics of children affected with pneumonia in the presence (group 1) or absence (group 2) of SARS-CoV-2 infection.

RESULTS

Overall, the main clinical manifestations at the admission were fever, cough, loss of appetite, fatigue/weakness, nasal congestion and/or rhinorrhea, and dyspnea. Based on the SARS-CoV-2 polymerase chain reaction (PCR) test, 24 positive children with pneumonia (group 1) and 20 negative children with pneumonia (group 2) were identified; 10 positive children did not show any radiological findings of pneumonia. No significant differences were found between the two pneumonia study groups for any clinical and laboratory parameters, except for C-reactive protein (CRP). Of course, both pneumonia groups showed increased CRP values; however, the COVID-19 pneumonia group 1 showed a significantly higher increase of CRP compared to group 2.

CONCLUSION

In our case series of children assessed for SARS-CoV-2 infection based on contact tracing, the acute inflammatory response and, in detail, CRP increase resulted to be more pronounced in COVID-19 children with pneumonia than in children with SARS-CoV-2-unrelated pneumonia. However, because of multiple limitations of this study, larger, controlled and more complete clinical studies are needed to verify this finding.

**Key Words:** Pediatric COVID-19; SARS-CoV-2; Pneumonia; C-reactive protein; Chest X-ray; Inflammatory parameters

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Zhamankulov A, Rozenson R, Morenko M, Akhmetova U, Tyo A, Poddighe D. Comparison between SARS-CoV-2 positive and negative pneumonia in children: A retrospective analysis at the beginning of the pandemic. *World J Exp Med* 2022; 12(2): 26-35

**URL:** https://www.wjgnet.com/2220-315x/full/v12/i2/26.htm

**DOI:** https://dx.doi.org/10.5493/wjem.v12.i2.26

**Core Tip:** This is a single-center pediatric case series of coronavirus 2019 disease (COVID-19) from Kazakhstan during the first wave of pandemic. We analyzed the main clinical aspects in those children diagnosed with pneumonia. In detail, we compared the clinical and laboratory characteristics of children affected with pneumonia in the presence (group 1) or absence (group 2) of severe acute respiratory syndrome coronavirus-2 infection. No significant differences were found between these study groups for any clinical and laboratory parameters, except for C-reactive protein (CRP). Of course, both pneumonia groups showed increased CRP values, overall; however, COVID-19 pneumonia group showed a significantly higher increase of CRP compared to pneumonia children without COVID-19.

**INTRODUCTION**

In December 2019, a new type of coronavirus infection rapidly spread from Wuhan city (in Hubei province, China), which was implicated in many cases of pneumonia and severe respiratory distress. On February 11th, 2020, the Research Group of the International Committee on Taxonomy of Viruses defined this new coronavirus as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), and the World Health Organization (WHO) named the related infectious disease as coronavirus 2019 disease (COVID-19). On March 11th, 2020, the WHO announced a pandemic of COVID-19[1-3]. The Republic of Kazakhstan borders with China, and the first case of COVID-19 was registered on March 13th, 2020, in Almaty city. Accordingly, several restrictions were promptly implemented like in most parts of the world, which also affected the general medical practice and patients’ management all over the country[4]. Overall, COVID-19 in children is characterized by a milder clinical course, in terms of both clinical manifestations and risk of complications[5]. According to the report from the American Academy of Pediatrics, as of September 17th, 2020 (thus, related to the first wave of pandemic), the proportion of pediatric COVID-19 diagnoses in the United States was only 10.3% of all the COVID-19 registered cases; the mortality rate in children was < 0.2%[6]. A study from China, including 2,143 pediatric patients, confirmed a mild clinical course of COVID-19 in most children and, indeed, only 5.9% of cases were diagnosed as severe in the same period[7]. Therefore, most pediatric COVID-19 cases showed an asymptomatic or mild clinical course[8-9]. The most commonly reported symptoms in children were fever and cough and, in general, respiratory manifestations (such as rhinorrhea, nasal congestion, undifferentiated upper airways inflammatory syndrome, dyspnea); however, gastrointestinal symptoms (including nausea, vomiting, abdominal pain, and diarrhea) were described as well[9-11]. Here, we reported a pediatric case series of COVID-19 from Kazakhstan. In detail, we analyzed the development of pneumonia in children medically and microbiologically assessed for SARS-CoV-2 infection in the context of a household contact tracing strategy implemented at the beginning of the pandemic.

**MATERIALS AND METHODS**

We retrospectively analyzed the medical records of 54 children aged 5 days to 17 years, who were medically assessed and hospitalized since they were close contacts of COVID-19 adult patients in their family setting. In detail, all these children were consecutively admitted and assessed at the Emergency Department of the multidisciplinary Children's Municipal Hospital No. 1 in Nur-Sultan (Kazakhstan), from June 8th to September 15th, 2020, because they were diagnosed with SARS-CoV-2 infection and/or affected with pneumonia. Indeed, this case series is a part of all those pediatric patients that received medical attention at the Emergency Department of Children's Municipal Hospital No. 1, because of previous close contact with a family member diagnosed with COVID-19, as already mentioned. All these children underwent SARS-CoV-2 polymerase chain reaction (PCR) test, but only those who resulted to be PCR positive and/or were diagnosed with pneumonia (even despite the negative PCR result), were admitted to the department of Pulmonology. Indeed, children who had contact with family members diagnosed with COVID-19 but resulted to be PCR negative and without pneumonia, were not admitted to the hospital and, thus, were discharged from the Emergency Department; unfortunately, these data could not be reliably retrieved. In order to assess the infection with SARS-CoV-2 in these children, the biospecimen was obtained by oropharyngeal swab, and the samples were placed in 3 mL of transport medium, in order to be delivered to the authorized laboratory according to the rules approved by the Ministry of Health of Republic of Kazakhstan (protocol No. 15990). The analysis of the viral RNA presence (by SARS-CoV-2 PCR test) was carried out by using the diagnostic kit KH-G-M-565-48-CE (manufactured by Shanghai Kehua Bio-engineering Co., Ltd; analyzer Xi'an Tian Long Science and Technology Co., Ltd., Shaanxi, China). Upon admission to the hospital, these children underwent a complete clinical examination (including an accurate collection of personal and family history) and first-level diagnostic work-up (including a complete blood cell count -CBC-, erythrocyte sedimentation rate -ESR-, urinalysis and general biochemistry). The biochemical analyses included plasmatic calcium, glucose, sodium, potassium, chloride, urea, creatinine, total protein, alanine aminotransferase, aspartate aminotransferase, bilirubin, creatine phosphokinase, in addition to serum C-reactive protein (CRP). All patients received a chest X-ray, in addition to the SARS-CoV-2 PCR test, as mentioned above. Additionally, according to the attending physician’s recommendation for individual patients, the coagulation panel (including D-dimer) and additional laboratory tests (such as procalcitonin, lactate dehydrogenase, vitamin D) were performed in some patients only. Moreover, based upon the actual clinical condition and previous results, some children variably received a chest computerized tomography, abdominal ultrasound, renal ultrasound, echocardiography, electrocardiogram, cranial sonography (in patients younger than 1 year). Whenever these children received this additional diagnostic work-up, it was performed within the first week after the hospital admission. The clinical monitoring was established based on individual patients’ condition. Temperature normalization, resolution of clinical symptoms, and 2 negative consecutive SARS-CoV-2 PCR tests were the adopted criteria to discharge these pediatric patients from the hospital. Data collection and descriptive analysis were carried out by Microsoft® Excel 2010 for Windows. Wherever appropriate and feasible, the statistical data analysis was performed: The differences in specific variables/parameters between two groups of patients were assessed for statistical significance by using the GraphPad Prism® software (version 4.0). In detail, laboratory parameters were expressed as mean ± SD error of the mean, because of the small and variable size of the study groups; accordingly, unpaired *t*-test (with Welch’s correction) was used to compare two groups: *P* value < 0.05 was considered statistically significant.

**RESULTS**

***Patients’ demographic and study groups***

Fifty-four children (age range: 5 days to 17 years; mean age and SD: 56 ± 55 mo) were assessed because of a positive SARS-CoV-2 PCR test and/or clinical/radiological finding of pneumonia after a close contact with a family member diagnosed with COVID-19.
 As graphically summarized in Figure 1, based on the SARS-CoV-2 PCR test and the radiological findings, 24 COVID-19 children with pneumonia (group 1) and 20 COVID-19 negative children with pneumonia (group 2) were identified, in addition to 10 SARS-CoV-2 PCR positive children who did not show any radiological findings of pneumonia. The detailed clinical and demographic characteristics of these 44 pneumonia children enrolled in the study are shown in Table 1. Overall, among all those 34 SARS-CoV-2 PCR positive children, 4 patients were completely asymptomatic (11.8%), 6 children were affected with upper airway acute respiratory infection (17.6%), and 24 patients developed mild to moderate pneumonia (70.6%). Among these 24 patients diagnosed with pneumonia (who represent our study population), the lung disease was bilateral in 17 cases, segmental in 5 cases, and subsegmental in 2 patients. Among those 20 SARS-CoV-2 PCR negative children diagnosed with lung disease, 15 children developed bilateral pneumonia and 5 patients showed unilateral subsegmental (always right-sided) pneumonia. All these radiological aspects are also summarized in Table 1.

***Patients’ clinical characteristics***

Overall, the main clinical manifestations at the admission were fever, cough (which was reported to be dry and not productive in most cases), loss of appetite, fatigue and weakness, nasal congestion and/or rhinorrhea, dyspnea, as summarized in Table 1. Gastrointestinal symptoms, such as vomiting/nausea, diarrhea, and flatulence, were unusual in our patients, and were mostly reported in children younger than 3 years. Only one 16-year patient complained of intense sweating, chest pain and dizziness, but he was affected with congenital heart disease (pulmonary artery stenosis). The differential descriptive analysis of all clinical manifestations according to the group designation is reported in Table 1. Therefore, the main chief complaints were fever and cough, overall. No statistically significant differences were noticed between these two groups in terms of frequency and type of clinical manifestations. Cough (overall, reported in around 72% of all pneumonia patients) was present in 70.8% and 75% patients of the COVID-19 positive and negative groups, respectively. Fever (that was detected in > 75% of the study participants, overall) was reported in 70.8% and 80% patients of COVID-19 positive and negative groups, respectively. As regards other concerning respiratory symptoms, dyspnea was detected in both groups without any statistical differences and, respectively, in 29.2% and 35% of COVID-19 positive and negative groups.

***Laboratory investigations***

All the available laboratory results are summarized in Table 2. No statistically significant differences were found between the study groups for any laboratory parameters, except for CRP. In detail, there was a statistically significant difference between COVID-19 positive and negative patients, in terms of CRP values (group 1: 41.47 ± 11.23 mg/L, group 2: 15.10 ± 4.21 mg/L; *P* = 0.0361). However, no inter-group significant differences were detected as regards ESR. In terms of CBC, no significant differences were detected between these pneumonia groups in the main hematological parameters (hemoglobin, thrombocytes count and total white blood cells). However, in terms of differential cell blood count (as described in Table 2), both groups of children with pneumonia showed a relative lymphocyte reduction and, conversely, neutrophil increase. As already mentioned, no significant differences were found for all the other biochemical parameters; however, as explained, these data were not available for all study participants as regards many parameters, which may have affected the results of the statistical analysis, of course.

***Other radiological investigations***

Unfortunately, data on additional radiological investigations were available for a minority of patients, except for abdominal ultrasound, which was performed in 34 patients: It resulted abnormal with diffuse and reactive changes in the liver in only 4 COVID-19 patients (11.8%), who actually did not complain of any abdominal symptoms. No additional ultrasonographic alterations were reported. In detail, as regards the kidneys, no pathological changes were observed at all. Only 3 children (complaining of chest pain) underwent chest ultrasound: All showed signs of a small pleural effusion. In detail, among these patients, 2 were diagnosed with COVID-19 and one was SARS-CoV-2 negative.

**DISCUSSION**

Currently, a few articles on COVID-19 from Central Asia can be retrieved in the medical literature: As regards the first wave of pandemic, those are mainly epidemiological studies describing the outbreak situation until June 2020[12-15]. Our study is a single-center pediatric case series describing the clinical, laboratory and radiological characteristics of SARS-CoV-2 positive and negative Kazakhstani children with pneumonia, who were identified based on contact tracing in the household setting.
The clinical manifestations of these COVID-19 children in our study were not qualitatively and quantitatively different from those emerging from previous and larger case series during the first phase of the pandemic[16-18]. Interestingly, > 60% of our patients were younger than 5 years; however, this distribution may be easily biased by the different parental awareness for infants and young children: Indeed, as explained, we assessed all consecutive pediatric contacts of COVID-19 adults, who were addressed for medical evaluation at the hospital. Respiratory symptoms were the most frequent clinical manifestations and were complicated with pneumonia in several patients. Among 54 pediatric contacts with family members affected with COVID-19, only 34 children resulted to be SARS-CoV-2 PCR positive, and 24 of them (70.6%) were concomitantly diagnosed with pneumonia. This diagnostic rate of pneumonia among COVID-19 children was quite high in our case series, compared to similar studies from different countries (see later), in which contact tracing strategy was the main method used for participants’ recruitment, like in the present study. For instance, Alsharrah *et al*[19] described a retrospective and monocentric case series including 134 pediatric COVID-19 patients who mostly (84%) acquired the infection from household contacts: 67.9% and 32.1% of these children were reported as asymptomatic or affected with mild symptoms or pneumonia, respectively. In detail, only 12 COVID-19 patients (around 9%) showed “abnormal chest X-ray findings”, which is clearly a much lower rate of COVID-19 pneumonia than in our experience presented in this study. Another study from Italy described children consulted in a specific COVID-19 Hub Centre coordinating the medical services, including children’s admission to the pediatric COVID-19 department of a single referral hospital. In this study, 208 children were assessed as suspected cases based on fever and/or respiratory symptoms, in addition to the exposure COVID-19-infected relatives or cohabitants. Out of 144 children who were SARS-CoV-2 PCR tested, 104 turned out positive, but only 30 children were admitted to the hospital for variable medical reasons: In most cases, the hospitalization was mainly driven by relative indications, such as the young age (< 12 mo) or the presence of pre-existing comorbidities, or the persistence of fever, rather than respiratory complications; as regards pneumonia specifically, these authors mentioned only 1 case in a 15-year girl[20].
As regards the type of lung involvement, in our case series no significant differences were noticed in terms of chest X-ray findings, between SARS-CoV-2 positive and negative patients with pneumonia. However, CRP values resulted to be statistically different between these two groups. CRP is the most widely used parameter for assessing the acute systemic inflammatory response in children requiring medical attention at the pediatric emergency department[21]. Our results are in contrast with the study by Zhao *et al*[22], who compared COVID-19 children (*n* = 23, all inpatient) with others diagnosed with Influenza A (*n* = 69, inpatient; *n* = 69, outpatient): Indeed, these authors reported the opposite situation, since CRP values were significantly higher in the latter disease than in COVID-19. However, the COVID-19 and Influenza A study groups included all types of patients in terms of clinical severity (30.4% and 40.6% children developed pneumonia, respectively) and not only those affected with pneumonia, unlike our present study. The patients’ age in this study was comparable to that of our cases series. Another study Li *et al*[23] made the same etiological comparison, but here all the enrolled children (COVID-19, *n* = 57; or Influenza A, *n* = 59) were affected with pneumonia: Again, CRP values resulted to be significantly lower in COVID-19 patients (3.7 mg/L *vs* 15.1 mg/L, *P* = 0.001). In this study, the average patients’ age was 18.7 mo and, thus, they were quite younger than ours. However, significant increases of CRP values were described in pediatric patients affected with severe forms. Therefore, our observations on CRP values are in contrast with the previous data from those few comparable studies and the general findings from larger clinical studies conducted during the first wave of pandemic. We cannot provide any clear explanation for our different observations, but we could speculate that our patients may have arrived at the medical attention at a later stage than what may have happened in other countries for some organizational reasons (*e.g.* different health system procedures; more rapid contact tracing system; others), and/or because additional viruses (*e.g.* Influenza A) were concomitantly implicated.
However, a number of study limitations might have definitely affected our results. Unfortunately, because of the limited resources for a complete diagnostic work-up in each patient at this hospital, the incomplete assessment of some laboratory parameters (including PCT, D-dimer and LDH) in all patients did not allow us to fully analyze the systemic inflammatory background in our case series, which may have provided further insights into our observations on the CRP values and radiological findings. In this regard, no computerized tomography imaging was immediately indicated at that time in children: Indeed, this is a retrospective cross-sectional study performed at the Emergency Department, and chest computerized tomography may have been requested later (and, thus, not recorded in the clinical database available to our research team) based on the individual medical indication. Indeed, no precise information about the therapy and, in detail, the use of antibiotics (such as macrolides, which were usually prescribed in this first phase of COVID-19 pandemic)[24] was available to us. Moreover, the small sample size and the absence of a control (SARS-CoV-2 negative) group without pneumonia have further hampered the data interpretation. Finally, the specific patients’ recruitment by family contact tracing might have affected these results as well.

**CONCLUSION**

In conclusion, in addition to a relatively high prevalence of pneumonia among Kazakhstani COVID-19 children diagnosed after contact tracing during the first wave of pandemic, we observed a significant difference in CRP values between SARS-CoV-2 positive and negative children affected with pneumonia, which may deserve further verification and investigations with larger clinical studies, due to the several limitations of this retrospective case series.

**ARTICLE HIGHLIGHTS**

***Research background***

Even though coronavirus 2019 disease (COVID-19) clinical course in children is much milder than in adults, pneumonia can occur in the pediatric population as well.

***Research motivation***

To report a single-center pediatric case series of COVID-19 from Kazakhstan during the first wave of pandemic.

***Research objectives***

To analyze the main clinical and laboratory aspects in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive and negative children diagnosed with pneumonia.

***Research methods***

Retrospective analysis of 54 children, who were medically assessed because they were close contacts of COVID-19 adults in their family setting, between June and September 2020. The clinical and laboratory characteristics of children affected with pneumonia in the presence (group 1) or absence (group 2) of SARS-CoV-2 infection, were compared.

***Research results***

No significant differences were found between the study groups for any clinical and laboratory parameters, except for C-reactive protein. Both pneumonia groups showed higher C-reactive protein values than COVID-19 children without pneumonia, overall; however, the COVID-19 pneumonia group 1 showed a significantly higher increase of C-reactive protein compared to group 2 (SARS-CoV-2 negative pneumonia).

***Research conclusions***

In our case series of children assessed for SARS-CoV-2 infection based on contact tracing, the acute inflammatory response and, in detail, C-reactive protein increase resulted to be more pronounced in COVID-19 children with pneumonia than in children with SARS-CoV-2 negative pneumonia.

***Research perspectives***

Larger, controlled and more complete clinical studies are needed to verify the different aspects of (acute) systemic inflammation in children with SARS-CoV-2 pneumonia.

**REFERENCES**

1 **Zhu N**, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W; China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med* 2020; **382**: 727-733 [PMID: 31978945 DOI: 10.1056/NEJMoa2001017]

2 **She J**, Liu L, Liu W. COVID-19 epidemic: Disease characteristics in children. *J Med Virol* 2020; **92**: 747-754 [PMID: 32232980 DOI: 10.1002/jmv.25807]

3 **Cucinotta D**, Vanelli M. WHO Declares COVID-19 a Pandemic. *Acta Biomed* 2020; **91**: 157-160 [PMID: 32191675 DOI: 10.23750/abm.v91i1.9397]

4 **Mukusheva Z**, Assylbekova M, Poddighe D. Management of pediatric rheumatic patients in Kazakhstan during the coronavirus disease 2019 (COVID-19) pandemic. *Rheumatol Int* 2020; **40**: 1351-1352 [PMID: 32514608 DOI: 10.1007/s00296-020-04613-5]

5 **Rabi FA**, Al Zoubi MS, Al-Iede MM, Kasasbeh G, Badran EF. Coronaviruses in children: A review of potential mechanisms of childhood protection. *Acta Paediatr* 2021; **110**: 765-772 [PMID: 33247469 DOI: 10.1111/apa.15691]

6 American Academy of Pediatrics and Children's Hospital Association. Children and COVID-19: State Data Report. Available from: https://downloads.aap.org/AAP/PDF/AAP and CHA - Children and COVID-19 State Data Report 7.30.20 FINAL.pdf

7 **Dong Y**, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, Tong S. Epidemiology of COVID-19 Among Children in China. *Pediatrics* 2020; **145** [PMID: 32179660 DOI: 10.1542/peds.2020-0702]

8 **Tiruneh FT**. Clinical Profile of Covid-19 in Children, Review of Existing Literatures. *Pediatric Health Med Ther* 2020; **11**: 385-392 [PMID: 33061744 DOI: 10.2147/PHMT.S266063]

9 **de Souza TH**, Nadal JA, Nogueira RJN, Pereira RM, Brandão MB. Clinical manifestations of children with COVID-19: A systematic review. *Pediatr Pulmonol* 2020; **55**: 1892-1899 [PMID: 32492251 DOI: 10.1002/ppul.24885]

10 **Zimmermann P**, Curtis N. COVID-19 in Children, Pregnancy and Neonates: A Review of Epidemiologic and Clinical Features. *Pediatr Infect Dis J* 2020; **39**: 469-477 [PMID: 32398569 DOI: 10.1097/INF.0000000000002700]

11 **Yasuhara J**, Kuno T, Takagi H, Sumitomo N. Clinical characteristics of COVID-19 in children: A systematic review. *Pediatr Pulmonol* 2020; **55**: 2565-2575 [PMID: 32725955 DOI: 10.1002/ppul.24991]

12 **Maukayeva S**, Karimova S. Epidemiologic character of COVID-19 in Kazakhstan: A preliminary report. *North Clin Istanb* 2020; **7**: 210-213 [PMID: 32478290 DOI: 10.14744/nci.2020.62443]

13 **Semenova Y**, Glushkova N, Pivina L, Khismetova Z, Zhunussov Y, Sandybaev M, Ivankov A. Epidemiological Characteristics and Forecast of COVID-19 Outbreak in the Republic of Kazakhstan. *J Korean Med Sci* 2020; **35**: e227 [PMID: 32567261 DOI: 10.3346/jkms.2020.35.e227]

14 **Kim K**, Choi JW, Moon J, Akilov H, Tuychiev L, Rakhimov B, Min KS. Clinical Features of COVID-19 in Uzbekistan. *J Korean Med Sci* 2020; **35**: e404 [PMID: 33230989 DOI: 10.3346/jkms.2020.35.e404]

15 **Bayesheva D,** Boranbayeva R, Turdalina B, Fakhradiyev I, Saliev T, Tanabayeva S, Zhussupov B, Nurgozhin T. COVID-19 in the paediatric population of Kazakhstan. Paediatr Int Child Health 2021; **41**:76-82 https://doi.org/10.1080/20469047.2020.1857101

16 **Ludvigsson JF**. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. *Acta Paediatr* 2020; **109**: 1088-1095 [PMID: 32202343 DOI: 10.1111/apa.15270]

17 **Hoang A**, Chorath K, Moreira A, Evans M, Burmeister-Morton F, Burmeister F, Naqvi R, Petershack M, Moreira A. COVID-19 in 7780 pediatric patients: A systematic review. *EClinicalMedicine* 2020; **24**: 100433 [PMID: 32766542 DOI: 10.1016/j.eclinm.2020.100433]

18 **Chang TH**, Wu JL, Chang LY. Clinical characteristics and diagnostic challenges of pediatric COVID-19: A systematic review and meta-analysis. *J Formos Med Assoc* 2020; **119**: 982-989 [PMID: 32307322 DOI: 10.1016/j.jfma.2020.04.007]

19 **Alsharrah D**, Alhaddad F, Alyaseen M, Aljamaan S, Almutairi N, Ayed M, Papenburg J, Alghounaim M. Clinical characteristics of pediatric SARS-CoV-2 infection and coronavirus disease 2019 (COVID-19) in Kuwait. *J Med Virol* 2021; **93**: 3246-3250 [PMID: 33219559 DOI: 10.1002/jmv.26684]

20 **Nunziata F**, Bruzzese E, Poeta M, Pierri L, Catzola A, Ciccarelli GP, Vassallo E, Montella E, Lo Vecchio A, Guarino A. Health-care organization for the management and surveillance of SARS-CoV-2 infection in children during pandemic in Campania region, Italy. *Ital J Pediatr* 2020; **46**: 170 [PMID: 33198780 DOI: 10.1186/s13052-020-00928-y]

21 **Poddighe D**. Common finding of mild hyponatremia in children evaluated at the Emergency Department and its correlation with plasma C-reactive protein values. *Minerva Pediatr* 2016; **68**: 173-176 [PMID: 27125438]

22 **Zhao Y**, Sun L, Bouchard HC, Zhang XX, Wan G, Hao YW, He SX, Jiang YY, Pang L. Coronavirus Disease 2019 *versus* Influenza A in Children: An Observational Control Study in China. *Biomed Environ Sci* 2020; **33**: 614-619 [PMID: 32933613 DOI: 10.3967/bes2020.080]

23 **Li Y**, Wang H, Wang F, Du H, Liu X, Chen P, Wang Y, Lu X. Comparison of hospitalized patients with pneumonia caused by COVID-19 and influenza A in children under 5 years. *Int J Infect Dis* 2020; **98**: 80-83 [PMID: 32535301 DOI: 10.1016/j.ijid.2020.06.026]

24 **Poddighe D**, Aljofan M. Clinical evidences on the antiviral properties of macrolide antibiotics in the COVID-19 era and beyond. *Antivir Chem Chemother* 2020; **28**: 2040206620961712 [PMID: 32972196 DOI: 10.1177/2040206620961712]

**Footnotes**

**Institutional review board statement:** Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by local Ethics Committee [protocol No. 2020.3.7 approved by Local Bioethical Committee of NJSC (Astana Medical University)] in agreement with the ethical principles of the State Standard for Good Clinical Practice and Regulatory Law of the Republic of Kazakhstan "On Science", State Educational Standard of the Republic of Kazakhstan 5.01.024-2008 "Scientific Research").
Informed Consent Statement: Informed consent was obtained from guardians of all patients involved in the study.

**Conflict-of-interest statement:** The authors have no conflict of interest to declare.

**Data sharing statement:** Dataset can be available upon request.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** October 30, 2021

**First decision:** December 27, 2021

**Article in press:** February 27, 2022

**Specialty type:** Infectious diseases

**Country/Territory of origin:** Kazakhstan

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Arumugam VA, India; Bersot CD, Brazil **S-Editor:** Xing YX **L-Editor:** A **P-Editor:** Xing YX

**Figure Legends**



**Figure 1 Flowchart describing the patients’ study enrollment according to the severe acute respiratory syndrome coronavirus-2 polymerase chain reaction testing and chest X-ray results.** COVID-19:Coronavirus disease 2019; PCR: Polymerase chain reaction.

**Table 1** **Clinical and demographic characteristics of the study participants at the hospital admission**

|  |  |  |
| --- | --- | --- |
|  | **Group 1** | **Group 2** |
| **(PCR+ pneumonia)** | **(PCR- pneumonia)** |
| **Patients** |  |  |
|  Number | 24 |  20 |
| **Gender** |  |  |
|  Male | 16 (66. 7%) | 9 (45.0%) |
|  Female | 8 (33. 3%) | 11(55.0%) |
| **Age** |  |  |
|  0-5 yr | 14 (58. 3%) | 11 (55.0%) |
|  5-10 yr | 4 (16. 7%) | 4 (20.0%) |
|  > 10 years | 6 (25. 0%) | 5 (25.0%) |
| **Clinical manifestations** |  |  |
|  Cough | 17 (70. 8%) | 15 (75.0%) |
|  Fever | 17 (70. 8%) | 16 (80. 0%) |
|  Dyspnea | 7 (29. 2%) | 7 (35. 0%) |
|  Loss of appetite | 15 (62. 5%) | 13 (65.0%) |
|  Fatigue | 15 (62. 5%) | 13 (65. 0%) |
|  Weakness | 15 (62. 5%) | 13 (65. 0%) |
|  Vomiting/nausea | 2 (8. 3%) | 3 (15. 0%) |
|  Diarrhea | 1 (4. 2%) | 0 (0. 0%) |
|  Flatulence | 1 (4. 2%) | 0 (0. 0%) |
|  Rhinorrhea | 8 (33. 3%) | 9 (45. 0%) |
|   Sweating | 0 (0. 0%) | 0 (0. 0%) |
|  Chest pain | 0 (0. 0%) | 0 (0. 0%) |
|  Dizziness | 1 (4. 2%) | 0 (0. 0%) |
|  Joint pain | 1 (4. 2%) | 0 (0. 0%) |
|  Seizures | 0 (0. 0%) | 0 (0. 0%) |
| **Chest X ray findings**  |  |  |
|  Bilateral pneumonia | 17 (70. 8%) | 15 (75. 0%) |
|  Segmental pneumonia | 5 (20. 8%) |  |
|  Subsegmental pneumonia  | 2 (8. 3%) | 5 (25.0%) |
| **Comorbidity** |  |  |
|  CHD | 1 (4. 2%) |  0 (0. 0%) |
|  PTI | 1 (4. 2%) |  0 (0. 0%) |
|  AML | 1 (4. 2%) |  0 (0. 0%) |
|  Partial epilepsy  | 0 (0. 0%) |  0 (0. 0%) |

CHD**:** Congenital heart disease; PTI: Idiopathic Thrombocytopenic Purpura, AML: Acute Myeloid Leukemia.

**Table 2 Laboratory parameters in the two study groups of children**

|  |  |  |
| --- | --- | --- |
| **Laboratory parameters** | **Group 1**  | **Group 2**  |
| **(PCR + pneumonia)** | **(PCR - pneumonia)** |
| ***n* = 24** | ***n* = 20** |
| HGB (g/L) | 120 ± 3.97 | 119 ± 3.4 |
| MCV (fL) | 85.2 ± 2.6 | 83.9 ± 1.59 |
| PLT (109/L) | 280 ± 19.4 | 338 ± 18.6 |
| WBC (109/L) | 10.3 ± 0.85 | 9.5 ± 0.77 |
| Lymphocytes (%) | 28.3 ± 2.91 | 32.9 ± 3.4 |
| Lymphocytes (109/L) | 2.7 ± 0.31 | 3.1 ± 0.35 |
| Neutrophils (%) | 64.3 ± 3.35 | 60.8 ± 3.8 |
| Neutrophils (109/L) | 7.3 ± 0.75 | 6.3 ± 0.69 |
| Monocytes (%) | 5 ± 0.47 | 6.1 ± 0.64 |
| Monocytes (109/L) | 0.5 ± 0.06 | 0.5 ± 0.06 |
| ESR (mm/h) | 19.1 ± 2.36 | 18.4 ± 1.88 |
| CRP (mg/L) | 41.5 ± 11.2 | 15.1 ± 4.21 |
| Total bilirubin (µmol/L) | 7.2 ± 0.67 | 9.07 ± 0.94 |
| Total proteins (g/L) | 66.5 ± 1.85 | 62.3 ± 1.56 |
| Creatinine (µmol/L) | 43 ± 2.84 | 41.6 ± 4.32 |
| Urea ( mmol/L) | 3.24 ± 0.29 | 3.47 ± 0.41 |
| Ca (mmol/L) | 2.25 ± 0.04 | 2.24 ± 0.05 |
| K (mmol/L) | 4.53 ± 0.24 | 4.79 ± 0.21 |
| Na (mmol/L) | 137 ± 0.50 | 138 ± 0.71 |
| Cl1 (mmol/L) | 102 ± 1.22 | 104 ± 1.18 |
| Glucose1 (mmol/L) | 4.66 ± 0.18 | 5.54 ± 0.58 |
| ALT1 (U/L) | 24.6 ± 8.24 | 24.4 ± 4.78 |
| AST1 (U/L) | 29.6 ± 3.88 | 30.5 ± 5.42 |
| CK1 (U/L) | 70.2 ± 18.7 | 64 ± 14.3 |
| LDH1 (U/L) | 399 ± 120 | 323 ± 189 |
| PCT1 (ng/mL) | 0.5 ± 0.11 | 0.3 ± 0.09 |
| D dimer1 (μg/mL) | 1.4 ± 0.35 | 0.1 ± 0.02 |
| 25 OH vitD1 (ng/mL) | 27.3 ± 3.79 | 25.3 ± 2.67 |

1The information is not available for all patients.

HGB: Hemoglobin; WBC: White blood cells; MCV: Mean corpuscular volume; ESR: Erythrocyte sedimentation rate; PLT: Platelets; CRP: C reactive protein; Ca: Total Calcium.; K: Potassium; Na: Sodium; Cl: Chloride; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; CK: Creatinkinase; LDH: Lactate dehydrogenase; PCT: Procalcitonin.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**